🇪🇸 Leer este artículo en español

⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist.

What if we attack HER2 twice at once?

In advanced HER2+ breast cancer we already have very powerful weapons. Antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) have changed the natural history of the disease, and tyrosine kinase inhibitors (TKIs) like tucatinib have shown activity even in brain metastases. But almost all patients eventually progress. The natural question: why not combine both strategies to attack HER2 via two distinct, non-crossing pathways?

That is exactly what HER2CLIMB-04 explores, a phase 2 study presented by Modi and colleagues in Clinical Breast Cancer.

The study

Simple and straightforward design: phase 2, single-arm, open-label, 70 patients with locally advanced or metastatic HER2+ who had progressed (or not tolerated) prior therapy directed at HER2 and a taxane. Median of 2 prior lines for advanced disease, median age 57 years. An important detail: entry was allowed with brain metastases, stable or even progressing.

The treatment combined oral tucatinib 300 mg twice daily + T-DXd on day 1 of each 21-day cycle. Primary endpoint: confirmed objective response rate (cORR) assessed by the investigator.

Key results

Endpoint	Result
cORR (primary)	51.4%
Duration of response	median 11.9 months (95% CI 6.0–not estimable)
Progression-free survival	median 11.5 months
Overall survival	median 28.4 months

In context: half of the heavily pretreated patients responded to the combination, and a median OS of 28 months in third line or later is no small feat (PMID: 42431148). The median of 2 prior lines places this population clearly in resistant disease territory.

Toxicity: what to watch for

The most frequent adverse effects were diarrhea (80%), nausea (77.1%) and fatigue (72.9%). A practical finding from the study: antidiarrheal prophylaxis, introduced in 44 patients, reduced diarrhea of any grade — a lesson directly applicable in clinical practice if this combination reaches the clinic.

🧐 Critical reading

Strengths: – Rational strategy: TKI + ADC with non-crossing mechanisms, attacking HER2 via two pathways. – Realistic and pretreated population, with brain metastases allowed — reflects clinical practice better than many trials that exclude them (PMID: 42431148). – Complete survival data and manageable toxicity with prophylaxis.

Limitations: – Phase 2, single-arm, no control group — we cannot quantify the incremental benefit of adding tucatinib versus T-DXd monotherapy. – N=70: small numbers for precise estimates (the 95% CI for DOR goes up to “not estimable”). – No randomized comparative data or formal brain metastasis subgroups. – The study does not answer whether this combination outperforms the classic sequence (T-DXd and, after progression, tucatinib).

💡 Implications

It does not change practice today, but it is a clear signal of where the strategy in HER2+ is heading: simultaneous dual blockade with TKI + ADC is viable, active and with manageable toxicity. Phase 3 studies are needed to know if the combination displaces the sequence. In the meantime, the message for clinicians: antidiarrheal prophylaxis should be routine in any regimen combining T-DXd, and this pretreated population still has options with durable responses.

Takeaway: In heavily pretreated advanced HER2+, tucatinib + T-DXd achieves a 51% response rate and median OS of 28 months, with manageable toxicity with prophylaxis — a promising combination awaiting phase 3 confirmation.

Reference: Modi S, Murthy RK, Chien AJ, et al. Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study. Clin Breast Cancer. 2026;26(8):21-30. DOI: 10.1016/j.clbc.2026.05.010 · PMID: 42431148

— This analysis was generated by ANGIE (Always Next to Guide, Inspire and Empower), an artificial intelligence system with SOUL profiles, designed by Dr. Javier Pumares Pérez.

Connect on LinkedIn · ppj.es